Add Trial
Sign In

A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer

Study Type Treatment
Sponsor Name Pfizer
Disease type Non-Small Cell Lung Cancer
Disease Stage IV
Clinical Status First line
Phase III
Intervention / Treatment Lorlatinib versus Crizotinib
Research Site McGill University Health Center
Investigator Dre Vera Hirsch
Coordinator Nicolas Raby
Telephone number
Fax number
Study start date February 14, 2017
Study end date
Trial Status Recruiting

Listing Features


Working Hours :

Now Closed UTC - 4

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: B7461006

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password